2022
First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
Fong K, Zhao J, Sultana R, Lee J, Lee S, Chan S, Yau T, Tai D, Sundar R, Too C. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. Liver Cancer 2022, 12: 7-18. PMID: 36872922, PMCID: PMC9982345, DOI: 10.1159/000526639.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaProgression-free survivalFirst-line systemic therapyBarcelona Clinic Liver CancerNetwork meta-analysisOverall survivalStandard of careAlpha-fetoproteinHazard ratioOS benefitSystemic therapyFirst-lineHepatocellular carcinomaFirst-line combination therapyRandom-effects network meta-analysisCombination of atezolizumabInhibitor monoclonal antibodiesFirst-line therapyCochrane Controlled Register of TrialsMeta-analysisKaplan-Meier curvesIndividual patient-level dataCochrane Controlled RegisterRegister of TrialsExtrahepatic spread
2021
“3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer
An O, Song Y, Ke X, So J, Sundar R, Yang H, Rha S, Lee M, Tay S, Ong X, Tan A, Ng M, Tantoso E, Chen L, Tan P, Yong W, Consortium S. “3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer. Cancer Research 2021, 81: 2788-2798. PMID: 33558338, DOI: 10.1158/0008-5472.can-20-2872.Peer-Reviewed Original ResearchConceptsAdvanced gastric cancerRNA editingRNA editing signaturesEditing levelsGastric cancerRNA editing eventsHigher editing levelsAdenosine-to-inosineRNA editing analysisGastric cancer cell linesPredictive biomarkersStratify patientsLevels of editingGene expression profilesPredicting response to chemotherapyEditing sitesEditing eventsMolecular subtypes of gastric cancerCancer cell linesPlatinum-based chemotherapyMetastatic gastric cancerSubtypes of gastric cancerCancer Genome AtlasFirst-line therapyResponse to chemotherapy